PUBLISHER: IMARC | PRODUCT CODE: 1468567
PUBLISHER: IMARC | PRODUCT CODE: 1468567
The global COPD and asthma devices market size reached US$ 45.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 69.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.
Chronic obstructive pulmonary disease (COPD) is an inflammatory disease that leads to obstructed airflow from the lungs. Its early symptoms include shortness of breath, wheezing, chest tightness, chronic cough with or without mucus, frequent cold, and throat soreness. On the other hand, asthma, also known as bronchial asthma, is a respiratory disorder that affects the airways in the lungs. Its symptoms are shortness of breath, chest tightness, trouble sleeping, and coughing or wheezing attacks. These respiratory diseases are treated using various devices that help deliver inhaled medication. COPD and asthma devices, also known as pulmonary drug delivery devices, are used as permanent treatment or rescue therapy for respiratory diseases. As a result, they are gaining immense traction across the globe.
The growing global geriatric population, which is highly susceptible to chronic respiratory disorders, represents one of the key factors positively influencing the market. In addition, rising occurrences of respiratory diseases caused due to the rising smoking of cigarettes are increasing the sales of COPD and asthma devices. Apart from this, the increasing expenditure on healthcare and continuous automation in the healthcare industry are contributing to the market growth. The widespread adoption of advanced medical solutions is offering lucrative growth opportunities to manufacturers across the globe. At present, healthcare practitioners and pulmonary diseases specialists are preferring a combination of a drug and a device on account of their fast and effective outcome. Furthermore, the expansion of chemical industries is resulting in the rising environmental pollution level and breathing problems, which, in turn, is driving the market. Additionally, the introduction of portable drug delivery devices is propelling the market growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global COPD and asthma devices market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, indication and distribution channel.
Inhalers
Drug Powdered Inhalers (DPIs)
Metered Dose Inhalers (MDIs)
Soft Mist Inhalers
Nebulizers
Compressor Nebulizers
Ultrasonic Nebulizers
Mesh Nebulizers
Asthma
COPD
Retail Pharmacies
Hospitals
Online Pharmacies
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Adherium Limited, Aristopharma Ltd., AstraZeneca PLC, Baxter International Inc., Boehringer Ingelheim International GmbH, Cohero Health Inc., Koninklijke Philips N.V., Omron Corporation, Pari Respiratory Equipment Inc., Recipharm AB and Verona Pharma plc.